OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company
OSR Holdings (NASDAQ: OSRH) has appointed Dr. Andreas Niethammer as Chief Medical Officer of its subsidiary Vaximm AG. Dr. Niethammer, who co-founded Vaximm, is returning to lead the clinical development of the company's oral T-cell activator platform, including the clinical-stage candidate VXM01.
With over 20 years of experience in cancer immunotherapy, Dr. Niethammer brings significant expertise from leadership roles at companies like Fate Therapeutics, NantKwest, and Pfizer. He originally developed the concept of oral T-cell vaccination at the Scripps Research Institute and has successfully advanced VXM01 into clinical trials for pancreatic cancer and glioblastoma.
OSR Holdings (NASDAQ: OSRH) ha nominato Dr. Andreas Niethammer Chief Medical Officer della sua controllata Vaximm AG. Il Dr. Niethammer, cofondatore di Vaximm, torna a guidare lo sviluppo clinico della piattaforma orale per l'attivazione delle cellule T dell'azienda, incluso il candidato in fase clinica VXM01.
Con oltre 20 anni di esperienza nell'immunoterapia oncologica, il Dr. Niethammer apporta una significativa competenza maturata in ruoli di leadership presso aziende come Fate Therapeutics, NantKwest e Pfizer. Ha sviluppato il concetto di vaccinazione orale delle cellule T presso il Scripps Research Institute e ha portato con successo VXM01 agli studi clinici per il cancro al pancreas e il glioblastoma.
OSR Holdings (NASDAQ: OSRH) ha nombrado a Dr. Andreas Niethammer como Director M茅dico de su subsidiaria Vaximm AG. El Dr. Niethammer, cofundador de Vaximm, regresa para liderar el desarrollo cl铆nico de la plataforma oral activadora de c茅lulas T de la compa帽铆a, incluyendo el candidato en fase cl铆nica VXM01.
Con m谩s de 20 a帽os de experiencia en inmunoterapia contra el c谩ncer, el Dr. Niethammer aporta una amplia experiencia adquirida en puestos de liderazgo en empresas como Fate Therapeutics, NantKwest y Pfizer. Originalmente desarroll贸 el concepto de vacunaci贸n oral de c茅lulas T en el Scripps Research Institute y ha avanzado con 茅xito VXM01 en ensayos cl铆nicos para c谩ncer de p谩ncreas y glioblastoma.
OSR Holdings (NASDAQ: OSRH)電� 鞛愴殞靷� Vaximm AG鞚� 斓滉碃 鞚橅暀 毂呾瀯鞛愲 Dr. Andreas Niethammer毳� 鞛勲獏頄堨姷雼堧嫟. Vaximm鞚� 瓿惦彊 彀诫鞛愳澑 Niethammer 氚曥偓電� 須岇偓鞚� 瓴疥惮鞖� T靹疙彫 頇滌劚頇� 頂岆灚韽缄臣 鞛勳儊 雼硠 頉勲炒氍检 VXM01鞚� 鞛勳儊 臧滊皽鞚� 鞚措亴旮� 鞙勴暣 氤店穩頄堨姷雼堧嫟.
20雲� 鞚挫儊鞚� 鞎� 氅挫棴旃橂 瓴巾棙鞚� 臧�歆� Niethammer 氚曥偓電� Fate Therapeutics, NantKwest, Pfizer 霌膘棎靹� 毽崝鞁� 鞐暊鞚� 靾橅枆頃橂┌ 頀嶋秬頃� 鞝勲靹膘潉 鞂撿晿鞀惦媹雼�. 攴鸽姅 Scripps Research Institute鞐愳劀 瓴疥惮鞖� T靹疙彫 氚膘嫚 臧滊厫鞚� 觳橃潓 臧滊皽頄堨溂氅�, VXM01鞚� 旆岇灔鞎旉臣 甑愲靹疙彫膦� 鞛勳儊 鞁滍棙旯岇 靹标车鞝侅溂搿� 歆勳爠鞁滌及鞀惦媹雼�.
OSR Holdings (NASDAQ : OSRH) a nomm茅 Dr. Andreas Niethammer directeur m茅dical de sa filiale Vaximm AG. Co-fondateur de Vaximm, le Dr Niethammer revient pour diriger le d茅veloppement clinique de la plateforme orale d鈥檃ctivation des cellules T de l鈥檈ntreprise, incluant le candidat en phase clinique VXM01.
Fort de plus de 20 ans d鈥檈xp茅rience en immunoth茅rapie contre le cancer, le Dr Niethammer apporte une expertise significative acquise lors de postes de direction chez Fate Therapeutics, NantKwest et Pfizer. Il a initialement d茅velopp茅 le concept de vaccination orale des cellules T au Scripps Research Institute et a fait progresser avec succ猫s VXM01 dans des essais cliniques pour le cancer du pancr茅as et le glioblastome.
OSR Holdings (NASDAQ: OSRH) hat Dr. Andreas Niethammer zum Chief Medical Officer seiner Tochtergesellschaft Vaximm AG ernannt. Dr. Niethammer, Mitbegr眉nder von Vaximm, kehrt zur眉ck, um die klinische Entwicklung der oralen T-Zell-Aktivator-Plattform des Unternehmens zu leiten, einschlie脽lich des klinischen Kandidaten VXM01.
Mit 眉ber 20 Jahren Erfahrung in der Krebsimmuntherapie bringt Dr. Niethammer umfassende Expertise aus F眉hrungspositionen bei Unternehmen wie Fate Therapeutics, NantKwest und Pfizer mit. Er entwickelte urspr眉nglich das Konzept der oralen T-Zell-Impfung am Scripps Research Institute und hat VXM01 erfolgreich in klinische Studien bei Bauchspeicheldr眉senkrebs und Glioblastom gebracht.
- None.
- None.
Dr. Niethammer is an internationally recognized oncology expert with over two decades of experience in cancer immunotherapy, clinical development, and translational medicine. He previously held leadership roles at global biopharmaceutical companies including Fate Therapeutics, NantKwest (now Immunity Bio), Pfizer, and more recently Aardvark Therapeutics, and has played a pivotal role in the development of novel immuno-oncology platforms, including VXM01.
Vaximm was co-founded by Dr. Niethammer to advance and commercialize therapeutic candidates based on his original publications on the concept of oral T-cell vaccination while at the Scripps Research Institute (Nature, 2002). Under his leadership, Vaximm successfully advanced lead candidate, VXM01, into first-in-human clinical studies for both pancreatic cancer and glioblastoma.
"We are thrilled to welcome Dr. Niethammer back to Vaximm as CMO leading Vaximm's clinical strategy," said Dr. Constance H枚fer, Chief Science Officer of OSRH. "His unique understanding of Vaximm's foundational scientific concepts, combined with his deep global clinical development experience, perfectly place him to both continue the clinical advancement of the lead candidate VXM01, and also to drive platform and pipeline expansion in oncology as well as other disease areas."
"I am honored to rejoin Vaximm at this exciting moment in its evolution," said Dr. Niethammer. "With OSR Holdings' support and resources, we are uniquely positioned to accelerate the development of powerful oral immunotherapies with the potential to improve outcomes for patients with difficult-to-treat cancers, as well as other diseases with high unmet needs where the Vaximm platform can potentially transform treatment options and outcomes."
Dr. Niethammer received his M.D. and Ph.D. from the University of Heidelberg and currently serves as an associate professor of oncology at Heidelberg University. He has authored numerous peer-reviewed publications and is widely regarded as a leader in T-cell鈥揵ased cancer vaccine development.
About听Vaximm AG
Vaximm, a wholly owned subsidiary of OSR Holdings Inc., is a Swiss-German biotech company focused on the development of oral T-cell immunotherapies for cancer. Its proprietary platform is designed to activate targeted cytotoxic T-cell responses via oral administration. Vaximm's lead program, VXM01, has completed Phase I/II clinical trials in pancreatic cancer and glioblastoma.
About OSR Holdings Inc.
OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare holding company dedicated to advancing biomedical innovation approaches to health and wellness to support global health outcomes. Through its subsidiaries, OSRH is engaged in immuno-oncology, regenerative biologics, and medical device distribution. OSRH's vision is to acquire and operate a portfolio of innovative healthcare and wellness companies, improving patient care through cutting-edge research and development.
Contact Information
OSR Holdings, Inc.
Investor Relations
[email protected]听
+82-31-948-9419
View original content to download multimedia:
SOURCE OSR Holdings Inc.
FAQ
Who is the new Chief Medical Officer of Vaximm AG?
What is Vaximm AG's main product candidate?
What is Dr. Niethammer's background and experience?
What technology does Vaximm AG develop?
What cancers is OSRH's VXM01 being tested for?
